The impact of metabolic disorders on the therapeutic efficacy and toxicity of amiodarone: mechanisms and management strategies
Open Access
- 4 November 2025
- journal article
- Published by Institute of Cytology and Genetics, SB RAS in Siberian Scientific Medical Journal
- Vol. 45 (5) , 91-110
Abstract
Amiodarone is one of the most effective and commonly prescribed class III antiarrhythmic agents. However, its pharmacokinetics may be impaired and toxicity may be aggravated by metabolic disorders. The review presents data showing that dyslipidemia, obesity, and type 2 diabetes mellitus significantly affect pharmacokinetics, pharmacodynamics and toxic profile of amiodarone. These conditions alter the drug’s binding to lipoproteins, the activity of cytochrome P450- dependent monooxygenases and tissue distribution, thereby increasing the risk of accumulation and toxic effects. Chronic heart failure further impairs drug metabolism and contributes to multisystem toxicity. The current clinical guidelines do not adequately address these critical aspects. Therefore, more rigorous monitoring of these patients and their plasma drug concentration (on individual basis) is suggested, along with a generally more cautious approach to amiodarone use. Future perspectives include prospective clinical trials on amiodarone, physiologically based pharmacokinetic modeling for personalized dosing, based on body mass index, lipid profile, and comorbidities, pharmacogenomic studies (cytochrome P450 polymorphisms), as well as biomarker discovery for drug toxicity prediction.Keywords
This publication has 93 references indexed in Scilit:
- Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HFEuropean Journal of Heart Failure, 2022
- Risk of severe hypoglycemic events from amiodarone‐sulfonylureas interactions: A population‐based nested case‐control studyPharmacoepidemiology and Drug Safety, 2020
- Liver Function and Prognosis, and Influence of Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection FractionEuropean Journal of Heart Failure, 2020
- Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic DrugsJAMA Cardiology, 2020
- Amiodarone versus other pharmacological interventions for prevention of sudden cardiac deathCochrane Database of Systematic Reviews, 2015
- Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of DrugsClinical Pharmacokinetics, 2012
- Prescribing AmiodaroneJAMA, 2007
- Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat‐meal rat modelsBiopharmaceutics & Drug Disposition, 2005
- Pharmacology and Pharmacokinetics of AmiodaroneThe Journal of Clinical Pharmacology, 1991
- Basic and Clinical Pharmacology of Amiodarone: Relationship of Antiarrhythmic Effects, Dose and Drug Concentrations to Intracellular Inclusion BodiesThe Journal of Clinical Pharmacology, 1989